Source
Author: unknown
Eli Lilly to buy genetic medicine developer Akouos for $487 million [Deals Market Headlines | Breaking Stock Market News | Reuters]
Related Posts
J&J Wins Partial Reversal of $1B Merger Milestone Loss: Implications for **Earnout Disputes** in Medtech M&A
Johnson & Johnson (NYSE: JNJ) secured a partial victory from Delaware's Supreme Court, overturning a key element of a $1 billion damages award tied to its 2019 $3.4 billion acquisition of...
Medtronic Is ‘Going on the Offense with Strategic M&A’
Medtronic is aggressively pursuing **tuck-in M&A** in the **low- to mid-single-digit billion-dollar range**, targeting cardiology and neuroscience to accelerate growth amid a resurgent **MedTech M&A...
Court Ruling Ends Edwards Lifesciences’ $1.2 Billion JenaValve Acquisition: FTC Blocks TAVR-AR Monopoly Play
A U.S. District Court ruling on January 9, 2026, has permanently halted Edwards Lifesciences' proposed $945 million to $1.2 billion acquisition of JenaValve Technology, following a Federal Trade...
Lilly Buys Inflammation Biotech Ventyx for $1.2 Billion: Strategic Bet on NLRP3, Parkinson’s and Cardiometabolic Disease
Eli Lilly’s $1.2 billion all-cash acquisition of Ventyx Biosciences is a targeted move to secure a differentiated, oral NLRP3 franchise and expand its footprint across cardiometabolic,...